|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
A10BA02
|
|
gptkbp:bioavailability
|
50-60%
|
|
gptkbp:brand
|
gptkb:Diabex
gptkb:Diaformin
gptkb:Metfogamma
gptkb:Metforal
gptkb:Riomet
gptkb:Siofor
gptkb:Dianben
gptkb:Glifor
gptkb:Obimet
gptkb:Glucophage_XR
gptkb:Glumetza_XR
gptkb:Fortamet
gptkb:Glucophage
gptkb:Glumetza
Fortamet XR
Riomet XR
|
|
gptkbp:CASNumber
|
657-24-9
|
|
gptkbp:contraindication
|
metabolic acidosis
renal impairment
|
|
gptkbp:eliminatedIn
|
renal excretion
|
|
gptkbp:halfLife
|
4-8.7 hours
|
|
gptkbp:hasInChIKey
|
gptkb:XZWYZXLIPXDOLR-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C4H11N5
|
|
gptkbp:hasSMILES
|
CN(C)C(=N)N=C(N)N
|
|
gptkbp:indication
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:isNotProteinBound
|
true
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
improves insulin sensitivity
decreases hepatic glucose production
decreases intestinal absorption of glucose
|
|
gptkbp:meltingPoint
|
223-226°C
|
|
gptkbp:molecularWeight
|
129.164
|
|
gptkbp:name
|
gptkb:Metformin
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB00238
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gastrointestinal upset
lactic acidosis
|
|
gptkbp:synonym
|
gptkb:Glucophage
gptkb:Metformina
gptkb:Metformine
|
|
gptkbp:target
|
gptkb:AMP-activated_protein_kinase
gptkb:mitochondrial_respiratory_chain_complex_I
|
|
gptkbp:bfsParent
|
gptkb:Nevirapine
|
|
gptkbp:bfsLayer
|
7
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
DB00238
|